Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells

@article{Karagiannis2003ActivityOH,
  title={Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells},
  author={Sophia N. Karagiannis and Qin Wang and Nicholas East and Frances Burke and Stephane Riffard and Marguerite G. Bracher and Richard G. Thompson and Stephen R. Durham and Lawrence B Schwartz and Frances R Balkwill and Hannah J. Gould},
  journal={European Journal of Immunology},
  year={2003},
  volume={33}
}
We have previously shown that a chimeric IgE antibody against the folic acid receptor (MOv18 IgE) inhibits tumor growth in a SCID mouse model of ovarian carcinoma. MOv18 IgE gave greater protection than the corresponding chimeric MOv18 IgG1. We have now confirmed these effects in a nude‐mouse model of ovarian carcinoma and have demonstrated for the first time that human monocytes are active in IgE antibody‐dependent cell‐mediated cytotoxicity. Injection of tumor‐bearing mice with PBMC and MOv18… Expand
IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
TLDR
It is demonstrated that IgE Abs can engage cell surface IgE receptors and activate effector cells against ovarian tumor cells in vitro and offer a framework for an improved immunotherapeutic strategy for combating solid tumors. Expand
Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells
TLDR
A three-color flow cytometric assay is developed to investigate the mechanism by which IgE receptors on U937 monocytes target and kill ovarian tumor cells and suggests the potential of tumor-specific IgE antibodies to activate effector cells in immunotherapy of ovarian cancer. Expand
Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1
TLDR
It is demonstrated here that anti-hCD20 IgE antibodies have in vitro cytotoxic activity when used with purified allergic effector cells derived from umbilical cord blood, suggesting that allergic effectors activated by IgE and cell surface antigens have the capacity to induce tumor cell death in vitro and in vivo. Expand
Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer.
TLDR
Preclinical studies of a mouse/human chimeric IgE antibody (MOv18 IgE), which is specific for the cancer-associated antigen folate receptor alpha, and different IgE antibodies with specificity for many other antigens already validated as targets for IgG suggest a wide potential for development of a novel class of antibody therapy. Expand
Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody‐dependent cell‐mediated cytotoxicity against pancreatic cancer cells
  • S. L. Fu, J. Pierre, +6 authors M. Bluth
  • Biology, Medicine
  • Clinical and experimental immunology
  • 2008
TLDR
Serum levels of IgE and sCD23 may serve as useful biomarkers for patients with pancreatic cancer and may be important in the immune response to this disease in that IgE‐directed therapy may help to direct treatment. Expand
IgE immunotherapy
TLDR
The properties that make IgE a contributor to the allergic response and a critical player in the protection against parasites are reviewed, which support IgE as a novel anti-cancer modality and suggest the potential of IgE immunotherapies in oncology. Expand
Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.
TLDR
Findings show how antitumor IgE reprograms monocytes and macrophages in the tumor microenvironment, encouraging the clinical use of IgE antibody technology to attack cancer beyond the present exclusive reliance on IgG. Expand
IgE Interacts with Potent Effector Cells Against Tumors: ADCC and ADCP
We examine the properties of IgE antibodies which may render them effective against tumors. This may be due to the uniquely high affinity of IgE antibodies for their Fc epsilon (Fcɛ) receptors andExpand
IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype
TLDR
Overall, anti-tumour IgE can potentiate pro-inflammatory signals, and prime tumour cell killing by human monocytes, and will inform the development of IgE monoclonal antibody therapies for cancer. Expand
The IgE Antibody and Its Use in Cancer Immunotherapy
TLDR
Advances of current technologies and experimental models, coupled with a better understanding of IgE-mediated immune effector mechanisms against targeted tumors, are expected to help elucidate the full potential of tumor-specific IgE antibodies for cancer immunotherapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Comparison of IgE and IgG antibody‐dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma
TLDR
The results suggest that the allergic reaction could be harnessed for the suppression of ovarian tumors by constructing chimeric IgE and IgG1 antibodies with murine V regions and human C regions corresponding to the MOv18 monoclonal antibody against the human ovarian tumor‐associated antigen, folate binding protein. Expand
Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components
TLDR
Analysis of the bispecific reagents indicated that hybrid MAbs are superior to the heteroconjugate as far as storage stability is concerned, and human immunoglobulins were unable to compete with the Fc receptor binding of the hybridMAbs and therefore, Fc fragment removal seems to be an essential step. Expand
Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
TLDR
The data suggest that the folate binding receptor is expressed on IGROV1 cells at a density sufficient to provide for optimal levels of antibody-mediated lysis using a single chimeric antibody directed at the folATE binding receptor. Expand
Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus
TLDR
The view that IgE-mediated cytotoxic mechanisms may play an immunologically specific antitumor surveillance role and that laboratory-induced antitumors IgE mAbs have the potential of specific therapeutic agents for in vivo destruction of tumor cells is supported. Expand
Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
TLDR
The chimeric IgG1 and IgG4 antibodies were nearly as effective as the parental CO17-1A antibody in inhibiting tumor growth in nude mice, indicating that chimeric igG1 antibody is superior in its antitumor activity. Expand
Murine interleukin-4 displays potent anti-tumor activity in vivo
TLDR
A potent, non-cell autonomous, anti-tumor effect of IL-4 which is effective against a wide range of tumor cell types in vivo is identified and seems to be mediated by an inflammatory infiltrate composed of eosinophils and macrophages. Expand
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
TLDR
It is demonstrated that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB. Expand
Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
TLDR
The in vivo lympholytic ability of CAMPATH-1G is very potent as compared with other monoclonal antibodies (MoAbs) and may have applications in therapy of lymphoid malignancies and as an immunosuppressive agent. Expand
An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.
TLDR
The observed regression of established tumor masses by localizedIL-4 action provides a rationale for exploring IL-4-mediated tumor killing as a potential therapy for human malignant disorders. Expand
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
TLDR
The results suggest that IgG1 might be the favoured IgG subclass for therapeutic applications in complement-dependent hemolysis and in antibody-dependent cell-mediated cytotoxicity using both human effector and human target cells. Expand
...
1
2
3
...